All News
$26,000 was saved over 3 months when this health system implemented change on how ENA panels were ordered (could only be obtained if ANA +); intervention aimed at inappropriate testing by ortho, IM, family med and neuro abst#0058 #ACR22 @rheumnow https://t.co/GoDHat6N3v
TheDaoIndex KDAO2011 ( View Tweet)
Pike et al. Deucravactinib (TYK2i) in SLE. + on SRI(4) week 32. + SRI(4),BICLA, LLDAS, CLASI-50, swollen and tender joint counts week 48. Strange, the lowest dose (3mg bd) seems best. @RheumNow #ACR22 Abstr#1117 #ACRbest https://t.co/o4902tvZs8 https://t.co/t8oeMRGUS7
Richard Conway RichardPAConway ( View Tweet)
@RheumNow interview with Dr. Lauren Smith on race differences in MMF responses in systemic sclerosis at #ACR22
@jhrheumatology @JHRheumFellows
https://t.co/aSRHiJoIkE
Eric Dein ericdeinmd ( View Tweet)
Karmacharya et al. Multimorbidity in PsO strongly influences incident PsA, >=2 comorbidities HR 2.53, >=5 comorbidities HR 3.19. Also higher for non-white, HR 4.02, and decreased with age. @RheumNow #ACR22 Abstr#1506 https://t.co/OFobRzhQVL https://t.co/IP08XlD66H
Richard Conway RichardPAConway ( View Tweet)
2000 IU/day vitamin D led to significantly reduced incidence of autoimmune diseases in Abs 1200 over 5.3 years, but after trial termination, protective effects dissipated and were no longer significant. #ACR22 @RheumNow https://t.co/sLwoxeCR3y https://t.co/47wpWXF1W7
Dr. Rachel Tate uptoTate ( View Tweet)
HCQ does not prevent RA in CCP+ pts w/out clinical arthritis!
Stop RA: RCT HCQ vs. PBO in pts at-risk
Interim analysis 140+ pts
RA development HCQ 34% vs. PBO 36%
Trial interrupted as met futility criteria.
https://t.co/n31OmsjLhM
Abs#1604 #ACR22 @RheumNow #ACRBest https://t.co/NVYS8kB5to
Aurelie Najm AurelieRheumo ( View Tweet)
2022 ACR G/L for Integrative RA Intervent #ACR22
1 strong rec: consistent exercisee
27 conditional recs:
Rehab, Mediterr diet, against other diets, self-mgmt/CBT/acupunct
Conditional against electrotherapy, chiropractor
No rec for diet supplem
BMI, 🚬: no RA spec recomm
@RheumNow https://t.co/cVFr6beQuJ
Eric Dein ericdeinmd ( View Tweet)
Patel @draditipatel et al. Delay in starting ACE-I in Scleroderma Renal Crisis increased need for dialysis 75.6% vs 16.7%, p=0.023. No effect on overall survival. 5-year mortality 70%, 1 year mortality 58%. @RheumNow #ACR22 Abstr#1530 https://t.co/cdYhEtqcHT https://t.co/lDWJto1cF0
Richard Conway RichardPAConway ( View Tweet)
Mease et al. PsA - Early DMARD initiators (=<1 year following diagnosis) greater improvement in outcomes than late initiators (at least in MDA) in CorEvitas. @RheumNow #ACR22 Abstr#1493 https://t.co/oadxbG8TKS https://t.co/245xVTcKx1
Richard Conway RichardPAConway ( View Tweet)
Nabi. Biosimilar to biosimilar IFX switch in DANBIO. High retention rate - 92% in originator-experienced equiv to normal drop off at 1 year on a biologic. Lower retention 83% in originator-naive switchers = likely nocebo effect @RheumNow #ACR22 Abstr#1112 https://t.co/oa1SawWWs4 https://t.co/iU3doB9jV4
Richard Conway RichardPAConway ( View Tweet)
New biomarkers of increased disease activity in PsA?
Tissue remodeling and inflammation (neutrophil activity and fibrosis) biomarkers showed best performance in differentiating PsA w/ flares and without.
Abs#1610 @RheumNow #ACR22 https://t.co/73ta7VXgTY
Robert B Chao, MD doctorRBC ( View Tweet)
Kiltz et al. Greater efficacy of secukinumab in normal BMI than high BMI AS patients. Decremental effect with increasing BMI. @RheumNow #ACR22 Abstr#1495 https://t.co/zwEmQsJmPT https://t.co/nOW2IbTc5t
Richard Conway RichardPAConway ( View Tweet)
Dörner et al. Remibrutinib (BTKi) in pSS. + study in pSS! Improved ESSDAI (disease activity), no effect ESSPRI (PRO), trend to improve salivary flow, + effect on multiple labs. @RheumNow #ACR22 Abstr#1113 https://t.co/m2rvXbqq7b https://t.co/jQLyP66zX9
Richard Conway RichardPAConway ( View Tweet)
Benesova et al. Higher treatment response to secukinumab in both male and female AS patients when diagnosed earlier. No such effect seen in PsA patients. Emphasises need to reduce diagnostic delay in AS. @RheumNow #ACR22 Abstr#1497 https://t.co/9g2zN85a33 https://t.co/LfvQFTKr69
Richard Conway RichardPAConway ( View Tweet)
Promising results for Izokibep in PsA
Ph2 RCT meets primary endpoint at Wk 16
ACR50: 13% PBO 48% 40mg IZO 52% 80mg IZO
MDA: 5% PBO 42% 40mg 39% 80mg
Results observed as soon as wk2
No new safety signal compared to IL17Ai
https://t.co/Gilhg5k36b
Abs#1597 #ACR22 @RheumNow https://t.co/VvxSRLtkFk
Aurelie Najm AurelieRheumo ( View Tweet)
Protective effect of #allopurinol in gout
Dose dependent reduction in risk of acute coronary syndrome in incident #Gout
#ACR22 @RheumNow abst#1582 https://t.co/PrEtRwvLvm
Bella Mehta bella_mehta ( View Tweet)
Abs 1187 apremilast may have beneficial effects on cardiometabolic measures including reductions in HbA1c in severely obese patients and reductions in weight and dz activity improvements in PsO/ PsA outcomes across all BMI categories. #ACR22 @RheumNow https://t.co/fCdJxz2IDk https://t.co/mLnwKQs539
Dr. Rachel Tate uptoTate ( View Tweet)
Enjoy the post-session adult beverage #ACR22 and #rheumtwitter but, choose wisely as Abs 1206 finds beer consumption was consistently assoc'd w/ higher serum urate levels, whereas sake showed only modest associations in both males and females. @RheumNow https://t.co/ETtU31iTZ0 https://t.co/keG5IN7LbC
Dr. Rachel Tate uptoTate ( View Tweet)
Catch our daily recap LIVE at 5pm ET. #ACR22 https://t.co/OpPcGhnWJ1
Dr. John Cush RheumNow ( View Tweet)
Dr. @Drbeckyg reminds us that self-reported, RA patient completed joint counts are good for tender and ok for swollen. Check out her videos for teaching joint counts to your patients - all under 8 minutes in total. #ACR22 @RheumNow https://t.co/E2wBsNFS12
Dr. Rachel Tate uptoTate ( View Tweet)